Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients.
Acta Derm Venereol
; 104: adv26663, 2024 Apr 04.
Article
em En
| MEDLINE
| ID: mdl-38576104
ABSTRACT
Drug-associated bullous pemphigoid has been shown to follow long-term gliptin (dipeptidyl-peptidase 4 inhibitors) intake. This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes. A retrospective study was conducted in a tertiary centre among diabetic patients exposed to gliptins between the years 2008-2021. Data including demographics, comorbidities, medications, and laboratory results were collected using the MDClone platform. Seventy-six patients with type 2 diabetes treated with dipeptidyl-peptidase 4 inhibitors who subsequently developed bullous pemphigoid were compared with a cohort of 8,060 diabetic patients exposed to dipeptidyl-peptidase 4 inhibitors who did not develop bullous pemphigoid. Based on a multivariable analysis adjusted for age and other covariates, Alzheimer's disease and other dementias were significantly more prevalent in patients with bullous pemphigoid (p = 0.0013). Concomitant use of either thiazide or loop diuretics and gliptin therapy was associated with drug-associated bullous pemphigoid (p < 0.0001 for both). While compared with sitagliptin, exposure to linagliptin and vildagliptin were associated with bullous pemphigoid with an odds ratio of 5.68 and 6.61 (p < 0.0001 for both), respectively. These results suggest gliptins should be prescribed with caution to patients with type 2 diabetes with coexisting Alzheimer's and other dementias, or patients receiving long-term use of thiazides and loop diuretics. The use of sitagliptin over linagliptin and vildagliptin should be preferred in these patients.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Penfigoide Bolhoso
/
Demência
/
Diabetes Mellitus Tipo 2
/
Inibidores da Dipeptidil Peptidase IV
Limite:
Humans
Idioma:
En
Revista:
Acta Derm Venereol
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Israel